PRINCETON, NJ – Oct. 5, 2018 – Certara today announced that it is participating in 40 sessions at the ninth American Conference on Pharmacometrics (ACoP9).
Certara Launches BaseCase® Portal™, Enabling Life Sciences Companies to Deliver Therapeutic Decision-making Apps to HCPs at the Point of Care
PRINCETON, NJ – Sept. 26, 2018 – Certara announced today the launch of its BaseCase Portal cloud-based platform, that allows for the rapid creation of fully-customizable mobile apps that connect live to mathematical models and algorithms, and help HCPs optimize treatment for individual patients.
PRINCETON, NJ – Sept. 13, 2018 – Certara announced today that it has acquired Pirana, a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
Certara’s D360 Version 10.5 Extends Platform’s Ability to Optimize Discovery Research Across Therapeutic Modalities
August 16, 2018 – Certara today announced the launch of D360 v10.5, the first in a series of releases focused on delivering biologic-relevant tools together with D360’s data access capabilities.
PRINCETON, NJ – Aug. 2, 2018 – Certara today reported that 95% of novel new drug approvals by the US Food and Drug Administration (FDA) in the first half of 2018 were supported by Certara software or services. Those results emphasize how much modeling and simulation has become an integral part of regulatory submissions and highlight Certara’s leadership role in the field.
Certara Experts Highlight Quantitative Systems Pharmacology’s Role in First-in-human Clinical Trials
PRINCETON, NJ – July 26, 2018 – Certara announced today that Clinical Pharmacology & Therapeutics has published its “Letter to the Editor” describing the important role that quantitative systems pharmacology can play in defining dosing criteria for first-in-human clinical trials, together with the European Medicines Agency’s response.
Certara Supports the Not-for-profit Biotechnology Company Medicines Development for Global Health (MDGH) on the FDA New Drug Approval of Moxidectin for the Treatment of River Blindness (Onchocerciasis), a Neglected Tropical Disease
PRINCETON, NJ – June 14, 2018 – Certara was privileged to participate as a key member of the Medicines Development for Global Health development team to achieve FDA approval of moxidectin.
Certara Launches Version 8.1 of its Industry-leading Phoenix PK/PD Modeling and Simulation Software; Introduces Professional Certification Program
PRINCETON, NJ – June 5, 2018 – Certara today announced the launch of Phoenix 8.1.
Certara Scientists to Present Model-informed Drug Development, Systems Pharmacology and MBMA Advances at PAGE 2018
PRINCETON, NJ – May 29, 2018 – Certara today announced its participation in 28 sessions at the Population Approach Group in Europe (PAGE) 2018 Annual Meeting. PAGE is a UK-based, nonprofit organization, which is committed to taking a population approach to data analysis.
Certara’s Analytica Laser Launches Market Access Radar Providing Biopharma and Medical Device Companies with Breaking News on Access to Health Technologies Globally
PRINCETON, NJ – May 21, 2018 – Certara today announced the launch of Analytica Laser’s Market Access Radar™, a three times weekly market access intelligence briefing. This market access data is also available via an easily searchable web portal.